Therapeutics and Clinical Risk Management

Aims & Scope

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.

The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary.

The journal will consider case reports but only if they make a valuable and original contribution to the literature.

As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.

The journal does not accept study protocols, animal-based or cell line-based studies.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Chemical Engineering, Medicine, Pharmacology, Toxicology and Pharmaceutics and Social Sciences, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Chemical Engineering, Medicine, Pharmacology, Toxicology and Pharmaceutics and Social Sciences, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 3,650.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

  Citation: 210

  Authors: Christophe, Eric, Sandrine

• Bortezomib (Velcade?) in the treatment of multiple myeloma

  Citation: 207

  Authors: Antonia, Gareth J, Faith E

• Comparison of echinocandin antifungals

  Citation: 152

  Authors: Gregory, Daryl D, Peggy L

• In vitro fertilization (IVF): a review of 3 decades of clinical innovation and technological advancement

  Citation: 138

  Authors: Jeff, Mark V

• Risk factors of allergic rhinitis: genetic or environmental?

  Citation: 90

  Authors: De-Yun

• Natalizumab: A new treatment for relapsing remitting multiple sclerosis

  Citation: 88

  Authors: Michael

• Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender

  Citation: 81

  Authors: Yvonne, Fatimah Bte Moideen, Shu Chuen

• Brimonidine in the treatment of glaucoma and ocular hypertension

  Citation: 75

  Authors: Louis B

• Azacytidine (Vidaza�) in the treatment of myelodysplastic syndromes

  Citation: 74

  Authors: Kavita, Ghulam J

• Treatment of pruritic diseases with topical calcineurin inhibitors

  Citation: 72

  Authors: Sonja, Funda, Thomas A, Elke